Vicebio, Next-generation Vaccine Biotech, To Be Acquired By Sanofi For US $1.6 Billion
July 22, 2025
Sanofi will gain access to Molecular Clamp technology that enables development of next-generation multivalent vaccines against respiratory pathogens and beyond Vicebio Ltd, a biopharmaceutical company